Dr. Melnick and Team Publishes Pivotal Paper in Cell Reports: Stage Set for Clinical Trials Using Experimental New Drug for Lymphoma (DLBCL)
On the heels of numerous advancements by the Melnick Lab, the latest breakthrough involves an experimental new drug that is capable of completely eradicating human lymphoma in mice after five doses. Published in Cell Reports (August 2013), this finding sets the stage for clinical trials that would use an experimental drug for the treatment of B-cell lymphoma (DLBCL). Dr. Melnick, who joined the Division of Hematology and Medical Oncology in 2008, established that Bcl6 is a master regulatory protein that causes aberrant growth and the survival of lymphoma cells. He was recently interviewed by Dean Glimcher discussing research breakthroughs throughout his career.
Click for Interview with the Dean |Read WCMC Press Release | Read article in Cell Reports